MRMD (MariMed) Cyclically Adjusted PS Ratio: (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is MariMed Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


MariMed  (OTCPK:MRMD) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


MariMed Cyclically Adjusted PS Ratio Related Terms


MariMed Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for MariMed's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MariMed Cyclically Adjusted PS Ratio Chart

MariMed Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.98 2.28 1.48 0.50 0.34

MariMed Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.26 0.55 0.34 0.24 0.23

MRMD vs RMTI, INIS, RAPH: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, MariMed's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MariMed Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, MariMed's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where MariMed's Cyclically Adjusted PS Ratio falls into.



MariMed Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

MariMed's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, MariMed's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.105/333.9520*333.9520
=0.105

Current CPI (Jun. 2026) = 333.9520.

MariMed Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.014 241.428 0.019
201612 0.022 241.432 0.030
201703 0.018 243.801 0.025
201706 0.025 244.955 0.034
201709 0.010 246.819 0.014
201712 0.009 246.524 0.012
201803 0.012 249.554 0.016
201806 0.016 251.989 0.021
201809 0.017 252.439 0.022
201812 0.016 251.233 0.021
201903 0.017 254.202 0.022
201906 0.110 256.143 0.143
201909 0.052 256.759 0.068
201912 0.023 256.974 0.030
202003 0.032 258.115 0.041
202006 0.039 257.797 0.051
202009 0.039 260.280 0.050
202012 0.065 260.474 0.083
202103 0.072 264.877 0.091
202106 0.088 271.696 0.108
202109 0.088 274.310 0.107
202112 0.093 278.802 0.111
202203 0.083 287.504 0.096
202206 0.087 296.311 0.098
202209 0.089 296.808 0.100
202212 0.094 296.797 0.106
202303 0.100 301.836 0.111
202306 0.101 305.109 0.111
202309 0.104 307.789 0.113
202312 0.103 306.746 0.112
202403 0.101 312.332 0.108
202406 0.107 314.175 0.114
202409 0.107 315.301 0.113
202412 0.102 315.605 0.108
202503 0.099 319.799 0.103
202506 0.101 322.561 0.105
202509 0.104 324.800 0.107
202512 0.105 324.054 0.108
202603 0.099 330.213 0.100
202606 0.105 333.952 0.105

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


MariMed Business Description

Other Exchanges MRMD:Canada
Address 10 Oceana Way, Floor 2, Norwood, MA, USA, 02062
MariMed Inc is a multi-state cannabis operator in the United States dedicated to improving lives every day through its high-quality products. The company develops, owns, and manages seed to sale state-licensed, regulatory-compliant facilities for the cultivation, production, and dispensing of medicinal and adult-use cannabis. It has created and continues to develop its own brands of cannabis flower, concentrates, edibles, and other precision-dosed products utilizing its proprietary strains and formulations. The company also licenses its proprietary brands, along with other top cannabis products, in select domestic markets. Its operations are conducted in compliance with applicable state and local laws and regulations in the jurisdictions in which it operates.